JP2023522213A - 再生非ステロイド性抗炎症組成物、その生産方法、及び使用方法 - Google Patents

再生非ステロイド性抗炎症組成物、その生産方法、及び使用方法 Download PDF

Info

Publication number
JP2023522213A
JP2023522213A JP2022563025A JP2022563025A JP2023522213A JP 2023522213 A JP2023522213 A JP 2023522213A JP 2022563025 A JP2022563025 A JP 2022563025A JP 2022563025 A JP2022563025 A JP 2022563025A JP 2023522213 A JP2023522213 A JP 2023522213A
Authority
JP
Japan
Prior art keywords
cell
disease
cells
syndrome
inflammatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022563025A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023522213A5 (enExample
Inventor
コロナド，ラモン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Crown Scientific LLC
Original Assignee
Crown Scientific LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crown Scientific LLC filed Critical Crown Scientific LLC
Publication of JP2023522213A publication Critical patent/JP2023522213A/ja
Publication of JP2023522213A5 publication Critical patent/JP2023522213A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/88—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving prostaglandins or their receptors
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0393—Animal model comprising a reporter system for screening tests
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/02—Atmosphere, e.g. low oxygen conditions
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7095—Inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Developmental Biology & Embryology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
JP2022563025A 2020-04-17 2021-04-16 再生非ステロイド性抗炎症組成物、その生産方法、及び使用方法 Pending JP2023522213A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063011373P 2020-04-17 2020-04-17
US63/011,373 2020-04-17
PCT/US2021/027674 WO2021211961A1 (en) 2020-04-17 2021-04-16 Regenerative nonsteroidal anti-inflammatory compositions, methods of production, and methods of use thereof

Publications (2)

Publication Number Publication Date
JP2023522213A true JP2023522213A (ja) 2023-05-29
JP2023522213A5 JP2023522213A5 (enExample) 2024-04-22

Family

ID=78084637

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022563025A Pending JP2023522213A (ja) 2020-04-17 2021-04-16 再生非ステロイド性抗炎症組成物、その生産方法、及び使用方法

Country Status (6)

Country Link
US (1) US20230190821A1 (enExample)
EP (1) EP4135729A4 (enExample)
JP (1) JP2023522213A (enExample)
AU (1) AU2021257255A1 (enExample)
CA (1) CA3175599A1 (enExample)
WO (1) WO2021211961A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240189364A1 (en) * 2021-02-26 2024-06-13 Arugula Sciences Llc Villi stromal cells compositions and uses thereof
JP2024544108A (ja) * 2021-12-24 2024-11-28 イーエイチジェイ アイピー リミテッド 胎盤組成物
CN116626303B (zh) * 2023-03-17 2026-04-14 重庆医科大学 槲皮素经scap/srebp2/nlrp3通路减轻脂多糖急性肺损伤的动物模型研究方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180280444A1 (en) * 2016-06-10 2018-10-04 Batu Biologics, Inc. Nanoparticle based tumor endothelial targeting vaccine
WO2019086912A1 (en) * 2017-11-06 2019-05-09 King's College London Therapeutic substances, their preparation and diagnostic procedure
WO2019169141A1 (en) * 2018-02-28 2019-09-06 Lester Smith Medical Research Institute Production and use of extracellular vesicles
JP2021535894A (ja) * 2018-06-11 2021-12-23 ヘルス、アンド、バイオテック、フランス(アッシュ、アンド、ベー、フランス)Health And Biotech France(H & B France) 間葉系幹細胞由来細胞外小胞

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101569168B1 (ko) * 2007-02-12 2015-11-13 안트로제네시스 코포레이션 태반 줄기세포를 이용한 염증 질환의 치료
US20150010609A1 (en) * 2010-02-18 2015-01-08 Osiris Therapeutics, Inc. Immunocompatible chorionic membrane products
SG11201609254YA (en) * 2014-05-07 2016-12-29 Osiris Therapeutics Inc Therapeutic placental compositions, methods of making and methods of use
US20200397990A1 (en) * 2018-02-28 2020-12-24 Regents Of The University Of Minnesota Multi-compartment syringe with pump mechanism

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180280444A1 (en) * 2016-06-10 2018-10-04 Batu Biologics, Inc. Nanoparticle based tumor endothelial targeting vaccine
WO2019086912A1 (en) * 2017-11-06 2019-05-09 King's College London Therapeutic substances, their preparation and diagnostic procedure
JP2021510805A (ja) * 2017-11-06 2021-04-30 キングス カレッジ ロンドンＫｉｎｇｓ Ｃｏｌｌｅｇｅ Ｌｏｎｄｏｎ 治療物質、それらの調製物及び診断手順
WO2019169141A1 (en) * 2018-02-28 2019-09-06 Lester Smith Medical Research Institute Production and use of extracellular vesicles
JP2021535894A (ja) * 2018-06-11 2021-12-23 ヘルス、アンド、バイオテック、フランス(アッシュ、アンド、ベー、フランス)Health And Biotech France(H & B France) 間葉系幹細胞由来細胞外小胞

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Apoptotic Cells, through Transforming Growth Factor-beta, Coordinately Induce Anti-inflammatory and", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 281(50), JPN7025000568, 2006, pages 38376 - 33384, ISSN: 0005530108 *

Also Published As

Publication number Publication date
EP4135729A4 (en) 2024-07-31
CA3175599A1 (en) 2021-10-21
EP4135729A1 (en) 2023-02-22
US20230190821A1 (en) 2023-06-22
WO2021211961A1 (en) 2021-10-21
AU2021257255A1 (en) 2022-11-24

Similar Documents

Publication Publication Date Title
JP7580202B2 (ja) 精製済み間葉系幹細胞組成物および間葉系幹細胞組成物を精製する方法
KR20220094194A (ko) 다능성 줄기 세포, 약제학적 조성물, 및 이의 제조 방법 및 이의 적용
KR101333664B1 (ko) 췌장 기능부전을 치료하기 위한 리파제, 프로테아제 및아밀라제 함유 조성물
US20170368106A1 (en) Methods for treating radiation or chemical injury
JP7617652B2 (ja) 筋萎縮性側索硬化症（ａｌｓ）および他の神経変性疾患の処置のための組成物および方法
US20230190821A1 (en) Regenerative nonsteroidal anti-inflammatory compositions, methods of production, and methods of use thereof
JP7549355B2 (ja) 間葉系間質細胞を拡大するための方法
JP2022101565A (ja) 無細胞胎盤調製物
KR20200030084A (ko) 씨디39 기질 줄기세포 단리 방법 및 용도
US20230121245A1 (en) Regenerative nonsteroidal anti-inflammatory compositions, methods of production, and methods of use thereof
AU2017328913A1 (en) Macrophage-based therapy for use in the treatment of liver injury
JP2013528230A (ja) ノーオプション重症虚血肢（ｃｌｉ）を処置するための組成物および方法
JP4804626B2 (ja) 免疫レギュレータ
JP2023522213A5 (enExample)
WO2014089397A1 (en) Compositions and methods of treating and preventing pulmonary fibrosis
Jungraithmayr The putative role of mast cells in lung transplantation
Xie et al. From stem cells to nanomedicine: A multimodal approach targeting pancreatic fibrosis via MFGE8-dependent ANXA1-SMAD2/3 axis
US20230158016A1 (en) Delta opioid receptor antagonists reprogram immunosuppressive microenvironment to boost immunotherapy
WO2023119239A1 (en) Method of treating severe graft versus host disease
US8765119B2 (en) Treating amyotrophic lateral sclerosis (ALS)with isolated aldehyde dehydrogenase-positive umbilical cord blood cells
WO2022046954A1 (en) Appl cells improved placental-derived adherent cells and methods of their use
CN121059676B (zh) 苦梀叶外泌体样纳米囊泡在治疗舍格伦综合征中的应用
US20240189364A1 (en) Villi stromal cells compositions and uses thereof
JP2010509360A (ja) 幹細胞移植を補助するためにＡＬＤＨｂｒ細胞を使用する方法
CN118526520A (zh) 一种能促进皮肤修复的外泌体制剂

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240410

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240410

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250218

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250826